ClinicalTrials.gg
CompletedNCT03497897Updated Aug 31, 2023Results posted

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

A Phase 2 interventional study of LYS006 20 mg and LYS006 2 mg in Inflammatory Acne, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in 6 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
187th of 354
66 · median 78
Started
2018
with 19 others
Phase 2
65 of 374
none open now
Registered
249th of 374
by date

Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 187th largest by enrollment of the 354 interventional ones that give a count, is one of 20 that started in 2018, is one of 65 in phase 2, and was the 249th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.

Read the detailed description

This was a randomized, placebo-controlled, subject- and investigator-blinded, multicenter, nonconfirmatory, parallel group, and proof-of-concept study in adult patients with moderate to severe inflammatory acne. After an initial screening period (up to 4 weeks), subjects were treated with LYS006 or matching placebo for 12 consecutive weeks to assess preliminary clinical efficacy, safety, and tolerability in the targeted subject population. At the beginning of the treatment period, subjects were randomized to one of three treatment groups, i.e., LYS006 20 mg twice daily (BID), LYS006 2 mg BID or matching placebo in a 3:1:3 ratio.

After treatment period completion, all subjects entered a post-treatment safety follow-up period of 4 weeks without study drug administration. The maximum duration of study participation was 20 weeks. Study completion was defined as when the last subject completed his/her study completion visit, and any repeat assessments associated with this visit were documented and followed-up appropriately by the investigator, or in the event of an early study termination decision, the date of that decision.

03

Conditions studied

  • Inflammatory Acne

Browse trials for

Keywords

  • Acne, efficacy, safety
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18 to 45 years of age inclusive, and otherwise in good health as determined by medical history, physical examination, vital signs, ECGs and laboratory tests at screening.
  • Body weight between 50 and 120 kg, both inclusive, at screening.
  • Patients with papulo-pustular acne vulgaris (inflammatory acne) presenting with 20 to 100 facial inflammatory lesions (papules, pustules and nodules) at baseline, no more than 2 facial inflammatory nodules or cysts at screening and baseline, and a minimun number of 10 non-inflammatory facial lesions (open and closed comedones).
  • Patients who are candidates for systemic treatment and for whom in the opinion of the investigator, an appropriate previous treatment with topical anti-acne medication failed, or was not well tolerated, or is not indicated (e.g., due to large body surface area affected, e.g., on the back)
  • Patients with Grade 3 (moderate) or Grade 4 (severe) IGA score assessed by the investigator at screening and baseline.

Exclusion criteria

Exclusion criteria:

  • Appropriate wash out periods are required for drugs, any oral/systemic treatment for acne, systemic or lesional injected (for acne) or systemic immunomodulators, any systemic hormonal treatments, previous treatment with biologics, oral retinoids (in particular isotretinoin) and any topical anti-acne treatment.
  • Previous surgical, physical (such as ThermaClear™), light (including blue or UV light, photodynamic therapy or laser therapy within 4 weeks prior to baseline
  • Use of facial medium depth chemical peels (excluding home regimens) within 3 months prior to baseline.
  • Any other forms of acne
  • Any severe, progressive or uncontrolled medical or psychiatric condition or other factors at randomization that in the judgment of the investigator prevents the patient from participating in the study.
  • Active systemic infections (other than common cold) during the 2 weeks prior to baseline.
  • History of immunodeficiency diseases, including a positive (ELISA and Western blot) test result at screening.
  • Chronic infection with or virus.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human chorionic gonadotropin (HCG) laboratory test.
  • Sexually active males or women of , defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of during dosing of study treatment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    LYS006 20 mg BID

    LYS006, 20 mg, orally, twice daily (BID), for 12 weeks

    Drug: LYS006 20 mg

  • Experimental
    LYS006 2 mg BID

    LYS006, 2 mg, orally, BID, for 12 weeks

    Drug: LYS006 2 mg

  • Placebo comparator
    Placebo BID

    Matching placebo, orally, BID, for 12 weeks

    Drug: Placebo

Interventions

  • LYS006 20 mg, capsules, oral administration, BID, for 12 weeks

  • LYS006 2 mg, capsules, oral administration, BID, for 12 weeks

  • DrugPlacebo

    Matching placebo, capsules, oral administration, BID, for 12 weeks

06

What researchers measure

Primary outcomes

  1. Total Inflammatory Lesion Count

    Inflammatory facial lesion count included papules, pustules, and nodules. The natural log transformed inflammatory facial lesion count up to Week 12 was analyzed using a Bayesian mixed effect model for repeated measurements (MMRM). Values estimated from the model at Week 12 are presented in the table. Posterior geometric mean and 90% credible intervals in each group are presented.

    Time frame: Week 12

07

Results

Posted Mar 20, 2023

Participant flow

Participants took part in 18 investigative sites in 6 countries.

Participant flow — Overall Study
MilestoneLYS006 20 mg BIDLYS006 2 mg BIDPlacebo BID
Started261129
Completed treatment period23924
Pharmacodynamic (pd) analysis set241128
Completed20923
Not completed626
Withdrew: Adverse event111
Withdrew: Lost to follow-up202
Withdrew: Physician decision100
Withdrew: Subject/guardian decision213

Outcome measures

PrimaryTotal Inflammatory Lesion Count

Inflammatory facial lesion count included papules, pustules, and nodules. The natural log transformed inflammatory facial lesion count up to Week 12 was analyzed using a Bayesian mixed effect model for repeated measurements (MMRM). Values estimated from the model at Week 12 are presented in the table. Posterior geometric mean and 90% credible intervals in each group are presented.

Time frame:
Week 12
Reported as:
Geometric mean · lesions
Total Inflammatory Lesion Count
lesionsLYS006 20 mg BIDLYS006 2 mg BIDPlacebo BID
Total Inflammatory Lesion Count18.55 (14.16 to 24.32)24.51 (16.35 to 36.94)20.04 (15.42 to 26.13)
Statistical analysis
  • LYS006 20 mg BID vs Placebo BID · Bayesian analysis · Posterior geometric mean ratio: 0.93 · 90% CI 0.64 to 1.3490% credible intervals are reported on the geometric means ratio
  • LYS006 20 mg BID vs Placebo BID · Bayesian analysis · P(geometric mean ratio<1): 0.637Posterior probability on geometric mean ratio is reported.
  • LYS006 20 mg BID vs Placebo BID · Bayesian analysis · P(geometric mean ratio<0.75): 0.171Posterior probability on geometric mean ratio is reported.

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 128 days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LYS006 20 mg BID0/26 (0%)0/26 (0%)10/26 (38.5%)
LYS006 2 mg BID0/11 (0%)0/11 (0%)8/11 (72.7%)
Placebo BID0/29 (0%)0/29 (0%)16/29 (55.2%)
Total0/66 (0%)0/66 (0%)34/66 (51.5%)
Most frequent other events
Showing 10 of 58
Most frequent other events
EventLYS006 20 mg BIDLYS006 2 mg BIDPlacebo BIDTotal
NasopharyngitisInfections and infestations3/263/113/299/66
Abdominal painGastrointestinal disorders0/262/110/292/66
Urinary tract infectionInfections and infestations0/262/112/294/66
HeadacheNervous system disorders0/262/113/295/66
EpistaxisRespiratory, thoracic and mediastinal disorders0/262/110/292/66
Crystal urine presentInvestigations2/260/114/296/66
Blood creatine phosphokinase increasedInvestigations2/261/113/296/66
TinnitusEar and labyrinth disorders0/261/110/291/66
DiarrhoeaGastrointestinal disorders0/261/110/291/66
NauseaGastrointestinal disorders1/261/111/293/66

Baseline characteristics

Age, Continuous
Age, Continuous(years)LYS006 20 mg BIDLYS006 2 mg BIDPlacebo BIDTotal
Mean23.2 ± 6.8924.5 ± 6.2325.0 ± 5.4024.2 ± 6.13
Sex: Female, Male
Sex: Female, Male(Participants)LYS006 20 mg BIDLYS006 2 mg BIDPlacebo BIDTotal
Female1682246
Male103720
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)LYS006 20 mg BIDLYS006 2 mg BIDPlacebo BIDTotal
Asian1113
Black or African American2169
Other2169
White2181645
08

Study locations

17 sites
  • Novartis Investigative Site
    Fremont, California 95438, United States
  • Novartis Investigative Site
    Santa Monica, California 90404, United States
  • Novartis Investigative Site
    Hialeah, Florida 33016, United States
  • Novartis Investigative Site
    New Orleans, Louisiana 70115, United States
  • Novartis Investigative Site
    Detroit, Michigan 48202, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Pflugerville, Texas 78660, United States
  • Novartis Investigative Site
    Plzen, 305 99, Czechia
  • Novartis Investigative Site
    Nice Cedex, 06202, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Bad Bentheim, 48455, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bonn, 53111, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Budapest, 1085, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Nijmegen, 6525EX, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Feb 2022, 41 months.

Results were first posted in Mar 2023, 1 year after primary completion.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 41 months is above that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2018
First posted
Apr 13, 2018
StartActual
Sep 10, 2018
Primary completionActual
Feb 24, 2022
CompletionActual
Mar 9, 2022
Results first posted
Mar 20, 2023
Last update
Aug 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03497897
Responsible party
Sponsor
First posted
Apr 13, 2018
Start date
Sep 10, 2018
Primary completion
Feb 24, 2022
Completion
Mar 9, 2022
Results posted
Mar 20, 2023
Last update
Aug 31, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LYS-006

Start the discussion